New oral anticoagulants in elderly patients

Stefano Barco; Yuk Wah Cheung; John W. Eikelboom; Michiel Coppens

doi:https://doi.org/10.1016/j.beha.2013.07.011

New oral anticoagulants in elderly patients

Stefano Barco, Yuk Wah Cheung, John W. Eikelboom, Michiel Coppens

Vascular Medicine (AMC)

Research output: Contribution to journal › Article › Academic › peer-review

70 Citations (Scopus)

Abstract

The new oral anticoagulants (NOACs) dabigatran etexilate, rivaroxaban, and apixaban have been extensively studied for prevention and treatment of venous thromboembolic disease and for stroke prevention in atrial fibrillation. Elderly patients have the highest incidence of thrombotic complications but also have the highest risk of anticoagulant associated bleeding. In this review we critically examine the balance between risks and benefits of NOACs compared with vitamin K antagonists in elderly patients enrolled in phase 3 randomized controlled trials for the management of venous thrombosis and stroke prevention in atrial fibrillation. Results show that the favourable balance between risks and benefits of NOACs is preserved in the elderly population

Original language	English
Pages (from-to)	215-224
Journal	Best practice & research. Clinical haematology
Volume	26
Issue number	2
DOIs	https://doi.org/10.1016/j.beha.2013.07.011
Publication status	Published - 2013

Access to Document

https://doi.org/10.1016/j.beha.2013.07.011

Cite this

@article{67a3f979fd364c068cabf26f4fe976ac,

title = "New oral anticoagulants in elderly patients",

abstract = "The new oral anticoagulants (NOACs) dabigatran etexilate, rivaroxaban, and apixaban have been extensively studied for prevention and treatment of venous thromboembolic disease and for stroke prevention in atrial fibrillation. Elderly patients have the highest incidence of thrombotic complications but also have the highest risk of anticoagulant associated bleeding. In this review we critically examine the balance between risks and benefits of NOACs compared with vitamin K antagonists in elderly patients enrolled in phase 3 randomized controlled trials for the management of venous thrombosis and stroke prevention in atrial fibrillation. Results show that the favourable balance between risks and benefits of NOACs is preserved in the elderly population",

author = "Stefano Barco and Cheung, {Yuk Wah} and Eikelboom, {John W.} and Michiel Coppens",

year = "2013",

doi = "https://doi.org/10.1016/j.beha.2013.07.011",

language = "English",

volume = "26",

pages = "215--224",

journal = "Best practice & research. Clinical haematology",

issn = "1521-6926",

publisher = "Bailliere Tindall Ltd",

number = "2",

}

TY - JOUR

T1 - New oral anticoagulants in elderly patients

AU - Barco, Stefano

AU - Cheung, Yuk Wah

AU - Eikelboom, John W.

AU - Coppens, Michiel

PY - 2013

Y1 - 2013

N2 - The new oral anticoagulants (NOACs) dabigatran etexilate, rivaroxaban, and apixaban have been extensively studied for prevention and treatment of venous thromboembolic disease and for stroke prevention in atrial fibrillation. Elderly patients have the highest incidence of thrombotic complications but also have the highest risk of anticoagulant associated bleeding. In this review we critically examine the balance between risks and benefits of NOACs compared with vitamin K antagonists in elderly patients enrolled in phase 3 randomized controlled trials for the management of venous thrombosis and stroke prevention in atrial fibrillation. Results show that the favourable balance between risks and benefits of NOACs is preserved in the elderly population

AB - The new oral anticoagulants (NOACs) dabigatran etexilate, rivaroxaban, and apixaban have been extensively studied for prevention and treatment of venous thromboembolic disease and for stroke prevention in atrial fibrillation. Elderly patients have the highest incidence of thrombotic complications but also have the highest risk of anticoagulant associated bleeding. In this review we critically examine the balance between risks and benefits of NOACs compared with vitamin K antagonists in elderly patients enrolled in phase 3 randomized controlled trials for the management of venous thrombosis and stroke prevention in atrial fibrillation. Results show that the favourable balance between risks and benefits of NOACs is preserved in the elderly population

U2 - https://doi.org/10.1016/j.beha.2013.07.011

DO - https://doi.org/10.1016/j.beha.2013.07.011

M3 - Article

C2 - 23953909

SN - 1521-6926

VL - 26

SP - 215

EP - 224

JO - Best practice & research. Clinical haematology

JF - Best practice & research. Clinical haematology

IS - 2

ER -